Showing results (111-120 of 150) with videos related to
Sort By:
Pageof 15
British Journal of Haematology|February 26, 2016
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network StudyJulie E Chang, Thomas Havighurst, KyungMann Kim, et al.Experimental and Therapeutic Medicine|March 5, 2011
Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic ResonanceJill M Kolesar, Kamakshi Sachidanandam, William R Schelman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2013
Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancerDonald M Cannon, Minesh P Mehta, Jarrod B Adkison, et al.European Journal of Cancer (Oxford, England : 1990)|November 20, 2013
Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)J R Brahmer, J W Lee, A M Traynor, et al.Cancer Chemotherapy and Pharmacology|December 12, 2012
Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trialU O Njiaju, A J Tevaarwerk, K Kim, et al.Cancer Chemotherapy and Pharmacology|December 17, 2008
A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumorsWilliam R Schelman, Sherry Morgan-Meadows, Rebecca Marnocha, et al.Respiratory Care|June 11, 2026
Association of Extubation Timing and Treatment Failure After Successful Extubation Readiness Trial in Pediatric PatientsKristopher L Dixon, Christie L Glau, Erica L Faulkner, et al.Cancer Chemotherapy and Pharmacology|April 14, 2010
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumorsAnne M Traynor, Maureen Hewitt, Glenn Liu, et al.Cancer Chemotherapy and Pharmacology|August 2, 2013
Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genesJill M Kolesar, Anne M Traynor, Kyle D Holen, et al.Cancer Chemotherapy and Pharmacology|January 22, 2016
A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumorsJustine Yang Bruce, Patricia M LoRusso, Priscila H Goncalves, et al.Pageof 15